Effect of moringa powder on blood pressure among hypertensive patients
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20264082Keywords:
Hypertension, Moringa powder, Quasi experimental testAbstract
Background: Hypertension, which is an increase in blood pressure, has a prevalence based on Riskesdas in 2018 at the age ≥18 years, which is around 34.1%. Various treatment methods have been developed because if hypertension is not treated it can cause symptoms and serious complications.
Methods: The study was conducted by using quantitative research approach and a Quasi experimental pre-test and post-test control research design was used. Total 40 participants (20 experimental and 20 control group) were selected by non-probability purposive sampling technique. Established the content validity of the tool from 22 experts of different areas. Corrections were made as per the suggestion and the final tool was prepared. The reliability co-efficient was done by using test-retest method and ‘r’ value is “0.9’’which is more than 0.7 so tool found that reliable.
Results: Experimental group mean was 143, standard deviation (SD) was 4.7016 and in control group mean was 172.5 and SD was 9.1046 and t-value Was 12.8748 and p value was 0.00001<0.05 is the systolic blood pressure among hypertensive patients and diastolic blood pressure in experimental group mean was 91, SD was 3.0779 and in control group mean was 107.5 SD was 7.8639 and p value is 0.00001 <0.05.
Conclusions: This reveals the systolic and diastolic BP after giving moringa powder on blood pressure among hypertensive patients was effective according to post-test in experimental and control group.
References
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359-62.
Centers for Disease Control and Prevention. Signs and symptoms of hepatitis C, 2023. Available at: https://www.cdc.gov/hepatitis-c/hcp/clinical-signs/index.html. Accessed 20 June 2026.
Rossi C, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, et al. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. J Hepatol. 2018;69(5):1007-14.
Konerman MA, Thomson M, Gray K, Moore M, Choxi H, Seif E, et al. Impact of an electronic health record alert in primary care on increasing hepatitis C screening and curative treatment for baby boomers. Hepatol. 2017;66(6):1805-13.
World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014. Available at: https://www.who.int/publications/i/item/9789241548755. Accessed 01 June 2026.
World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, 2016. Available at: https://iris.who.int/bitstream/handle/10665/204452/WHO_HIV_2016.01_eng.pdf?sequence=1. Accessed 01 June 2026.
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, 2018. Available at: https://www.who.int/publications/i/item/9789241550345. Accessed 01 June 2026.
World Health Organization. Guidelines on hepatitis B and C testing, 2017. Available at: https://www.who.int/publications/i/item/9789241549981. Accessed 20 June 2026.
World Health Organization. Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics, 2022. Available at: https://www.who.int/publications/i/item/9789240052734. Accessed 20 June 2026.
World Health Organization. Hepatitis C, 2026. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 06 October 2026.
Panel AI. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Hepatol. 2018;67(4):1470-1500.
Ghany MG, Morgan TR. Hepatitis C guidance 2020 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatol. 2020;72(2):681-722.
Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41.
Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415.
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatol. 2015;61(1):77-87.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sudaivi Prabhakar Kadam, Satish Nagkumar Salvi, Snehalata Sumanth Reddy, Nirmala Ashish Londhe, Rohit Kamble
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
